Randomized phase 2 study comparing irinotecan versus amrubicin as maintenance therapy after first-line induction therapy for extensive disease small cell lung cancer (HOT1401/NJLCG1401).

Hisashi TanakaYukihiro HasegawaYuka FujitaAtsushi NakamuraEiki KikuchiYasutaka KawaiToshiyuki HaradaNaomi WatanabeHiroshi YokouchiKazuhiro UsuiRyota SaitoHiroshi WatanabeTomomi MasudaTatsuro FukuharaKeita KudoRyoichi HondaSatoshi OizimiMakoto MaemondoAkira InoueNaoto Morikawa

Published in: Thoracic cancer (2021)

Maintenance therapy with CPT-11 or AMR after induction therapy might be effective in some patients.

Keyphrases

small cell lung cancer
open label
double blind
end stage renal disease
ejection fraction
newly diagnosed
clinical trial
stem cells
placebo controlled
randomized controlled trial
prognostic factors
phase iii
cell therapy